Publications by authors named "Frederic Mack"

Claim this Profile
H
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Johannes Weller, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel

Lancet Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Sied Kebir, Christina Schaub, Nina Junold, Elke Hattingen, Niklas Schäfer, Frederic Mack

J Neurooncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel

Lancet· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Christina Schaub, Sied Kebir, Nina Junold, Elke Hattingen, Niklas Schäfer, Frederic Mack

J Cancer Res Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Niklas Schäfer, Martin Proescholdt, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Frederic Mack

Neuro Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Christina Schaub, Julia Tichy, Niklas Schäfer, Kea Franz, Frederic Mack

J Neurooncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.
Christina Schaub, Niklas Schäfer, Frederic Mack, Moritz Stuplich, Sied Kebir

J Cancer Res Clin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
Niklas Schäfer, Gerrit H Gielen, Sied Kebir, Anja Wieland, Andreas Till, Frederic Mack

J Cancer Res Clin Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Sied Kebir, Rolf Fimmers, Norbert Galldiks, Niklas Schäfer, Frederic Mack

Clin Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Ulrich Herrlinger, Niklas Schäfer, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Frederic Mack

J Clin Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.
Sied Kebir, Florian C Gaertner, Marcus Mueller, Michael Nelles, Matthias Simon, Frederic Mack

Oncol Lett· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Frederic Mack, Niklas Schäfer, Sied Kebir, Moritz Stuplich, Christina Schaub

Oncology· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Christina Schaub, Susanne Greschus, Mirko Seifert, Andreas Waha, Elias Blasius, Frederic Mack

Oncology· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy.
Sied Kebir, Klaus Kuchelmeister, Pitt Niehusmann, Michael Nelles, Young Kim, Frederic Mack

Exp Hematol Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Moritz Stuplich, Dariusch R Hadizadeh, Klaus Kuchelmeister, Jasmin Scorzin, Christian Filss, Frederic Mack

J Clin Oncol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis